Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000673616 | SCV000798841 | uncertain significance | Deficiency of steroid 11-beta-monooxygenase | 2018-03-27 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000673616 | SCV005059293 | likely pathogenic | Deficiency of steroid 11-beta-monooxygenase | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004702305 | SCV005204539 | likely pathogenic | Congenital adrenal hyperplasia | 2024-06-20 | criteria provided, single submitter | clinical testing | Variant summary: CYP11B1 c.1145T>G (p.Leu382Arg) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250738 control chromosomes. c.1145T>G has been reported in the literature in the compound heterozygous state in a female individual with a diagnosis of classic 11-beta-hydroxylase deficiency (Mooij_2015). This suggests the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and found that the variant results in a complete loss of CYP11B1 enzymatic activity in vitro (Mooij_2015). The following publication has been ascertained in the context of this evaluation (PMID: 26053152). ClinVar contains an entry for this variant (Variation ID: 557468). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Fulgent Genetics, |
RCV005046906 | SCV005675068 | likely pathogenic | Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remediable aldosteronism | 2024-06-20 | criteria provided, single submitter | clinical testing |